云顶新耀(01952)维适平®获国家药监局批准上市 开启中重度溃疡性结肠炎口服新时代

Core Insights - The approval of VELSIPITY® (Argenine Acquimod Tablets) by the NMPA marks a significant advancement for the company in the treatment of moderate to severe active ulcerative colitis (UC) in adults, filling a critical gap in the market [1][2] - The drug is expected to reach peak sales of 5 billion RMB, becoming a core product alongside the existing drug in the nephrology field, indicating a new phase of rapid growth for the company [1][6] Group 1: Product Approval and Market Potential - VELSIPITY® is a next-generation high-selectivity S1P receptor modulator that offers rapid onset and effective deep mucosal healing, providing a new first-line treatment option for UC patients [1][3] - The incidence of UC in China is rising, with projections indicating an increase from approximately 980,000 patients in 2025 to about 1.5 million by 2031, highlighting the growing need for effective treatments [2] - Current treatment options are limited, with only 24% of UC patients achieving mucosal healing, underscoring the unmet clinical needs that VELSIPITY® aims to address [2][3] Group 2: Clinical Efficacy and Recognition - Clinical trials have shown that VELSIPITY® has a clinical remission rate of 48.1% and a mucosal healing rate of 51.9% after 40 weeks of maintenance treatment, demonstrating its significant clinical advantages [3][4] - The drug has been included in major international clinical guidelines, such as the 2024 AGA guidelines and the 2025 ACG guidelines, receiving strong recommendations for its use in moderate to severe UC [4] Group 3: Commercialization Strategy and Growth - The company has developed a comprehensive A2MS (Access, Medical, Market, Sales) operational system to efficiently promote VELSIPITY®'s market entry and maximize its therapeutic value [5][6] - The approval of VELSIPITY® signifies a major breakthrough in the autoimmune disease sector, enhancing the company's product matrix and expected to significantly boost revenue and profitability [6][7] - The company aims to achieve over 10 billion RMB in revenue by 2028 and over 15 billion RMB by 2030, with a projected annual growth rate exceeding 50% from 2025 to 2030 [7]